home / stock / bcda / bcda news

BCDA News and Press, BioCardia Inc. From 05/10/23

Stock Information
Company Name: BioCardia Inc.
Stock Symbol: BCDA
Market: NASDAQ
Website: biocardia.com
Menu
BCDA BCDA Quote BCDA Short BCDA News BCDA Articles BCDA Message Board
Get BCDA Alerts

News, Short Squeeze, Breakout and More Instantly...
BCDA - BioCardia, Inc. (BCDA) Q1 2023 Earnings Call Transcript

2023-05-10 20:25:04 ET BioCardia, Inc. (BCDA) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Miranda Peto – Investor Relations Peter Altman – President and Chief Executive Officer Dave McClung – Chief Financial ...
BCDA - BioCardia GAAP EPS of -$0.17 in-line

2023-05-10 16:24:39 ET BioCardia press release ( NASDAQ: BCDA ): Q1 GAAP EPS of -$0.17 in-line. Revenues were approximately $64 thousand for the three months ended March 2023, compared to approximately $60 thousand for the three months ended March 2022. For further d...

BCDA - BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on...

BCDA - BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377...
BCDA - BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, ...

BCDA - BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases has made available two presentations from the “Next Generation Cardiovascular...

BCDA - BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologie...
BCDA - BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript

2023-03-29 22:38:02 ET BioCardia, Inc. (BCDA) Q4 2022 Earnings Conference Call March 29, 2023, 04:30 PM ET Company Participants Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Kumarag...

BCDA - BioCardia GAAP EPS of -$0.67 misses by $0.02, revenue of $1.4M beats by $1.35M

2023-03-29 16:03:39 ET BioCardia press release ( NASDAQ: BCDA ): FY GAAP EPS of -$0.67 misses by $0.02 . Revenue of $1.4M (+40.0% Y/Y) beats by $1.35M . Research and development increased to $8.8 million in 2022, compared to $8.6 million in 2021, primarily due ...

BCDA - BioCardia GAAP EPS of -$0.67, revenue of $1.4M

2023-03-29 08:33:43 ET BioCardia press release ( NASDAQ: BCDA ): FY GAAP EPS of -$0.67. Revenue of $1.4M (+40.0% Y/Y). Research and development increased to $8.8 million in 2022, compared to $8.6 million in 2021, primarily due to increased expenses in support of the Ca...
Previous 10 Next 10